IPSEF - Ipsen reports Q3 results; reaffirms FY 23 guidance
2023-10-26 03:55:25 ET
More on Ipsen S.A., Ipsen S.A., etc.
- Exelixis lead product hits main goal in Phase 3 prostate cancer trial
- Ipsen wins FDA approval of rare bone disease drug palovarotene
- Historical earnings data for Ipsen S.A.
- Dividend scorecard for Ipsen S.A.
- Financial information for Ipsen S.A.
For further details see:
Ipsen reports Q3 results; reaffirms FY 23 guidance